Literature DB >> 12037643

Upper abdominal obesity, insulin resistance and breast cancer risk.

B A Stoll1.   

Abstract

PURPOSE: A majority of prospective studies show breast cancer risk to be higher in obese postmenopausal women with upper abdominal adiposity than in those with overall adiposity. The evidence is more limited and inconsistent in the case of premenopausal women. The review examines evidence that aberrant insulin signalling may be involved in the promotion of mammary carcinogenesis. The aetiology and concomitants of abdominal visceral obesity are examined. MECHANISMS: Clinical and experimental evidence suggests that the higher breast cancer risk associated with greater abdominal visceral obesity may be related to aberrant insulin signalling through the insulin receptor substrate 1 pathway, leading to insulin resistance, hyperinsulinaemia and increased concentrations of endogenous oestrogen and androgen. The putative role of aberrant insulin signalling in the promotion of mammary carcinogenesis may help to explain clinical relationships between breast cancer risk and age at menarche, pregnancies and onset of obesity.
CONCLUSION: Overall adiposity in women adversely affects breast cancer risk mainly by greater exposure of mammary epithelial tissue to endogenous oestrogen. Upper abdominal adiposity appears to involve an additional effect related to the presence of insulin resistance. Aetiological factors in the development of hyperinsulinaemic insulin resistance are still uncertain but may involve aberrant susceptibility genes in adipocyte insulin receptors or in the insulin receptor substrate 1 pathway. Epigenetic factors are also likely to contribute, including high free fatty acid levels and obesity. Dietary fatty acids, particularly polyunsaturated fatty acids, are known to regulate adipocyte differentiation through the nuclear peroxisome proliferator-activated receptor gamma, and may also have a role in insulin resistance. These aetiological factors are likely to be relevant to the high risk of postmenopausal breast cancer in industrialised Western populations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12037643     DOI: 10.1038/sj.ijo.0801998

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  28 in total

1.  Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.

Authors:  Debora Macis; Sara Gandini; Aliana Guerrieri-Gonzaga; Harriet Johansson; Paolo Magni; Massimiliano Ruscica; Matteo Lazzeroni; Davide Serrano; Massimiliano Cazzaniga; Serena Mora; Irene Feroce; Maria Pizzamiglio; Maria Teresa Sandri; Marcella Gulisano; Bernardo Bonanni; Andrea Decensi
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  An association between a common variant (G972R) in the IRS-1 gene and sex hormone levels in post-menopausal breast cancer survivors.

Authors:  Jing Fan; Roberta McKean-Cowdin; Leslie Bernstein; Frank Z Stanczyk; Arthur Xuejun Li; Rachel Ballard-Barbash; Anne McTiernan; Richard Baumgartner; Frank Gilliland
Journal:  Breast Cancer Res Treat       Date:  2006-06-05       Impact factor: 4.872

3.  Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: what is the link?

Authors:  Douglas A Corley
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

4.  Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer.

Authors:  Teoman Coskun; Funda Kosova; Zeki Ari; Aslan Sakarya; Yavuz Kaya
Journal:  Mol Clin Oncol       Date:  2016-03-10

5.  27-hydroxycholesterol is an endogenous selective estrogen receptor modulator.

Authors:  Carolyn D DuSell; Michihisa Umetani; Philip W Shaul; David J Mangelsdorf; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2007-09-13

6.  CREB-regulated transcription co-activator family stimulates promoter II-driven aromatase expression in preadipocytes.

Authors:  Nirukshi U Samarajeewa; Maria M Docanto; Evan R Simpson; Kristy A Brown
Journal:  Horm Cancer       Date:  2013-04-13       Impact factor: 3.869

7.  Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.

Authors:  Amanda I Phipps; Kathleen E Malone; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07-29       Impact factor: 4.254

8.  A high protein moderate carbohydrate diet fed at discrete meals reduces early progression of N-methyl-N-nitrosourea-induced breast tumorigenesis in rats.

Authors:  Christopher J Moulton; Rudy J Valentine; Donald K Layman; Suzanne Devkota; Keith W Singletary; Matthew A Wallig; Sharon M Donovan
Journal:  Nutr Metab (Lond)       Date:  2010-01-10       Impact factor: 4.169

Review 9.  Putative environmental-endocrine disruptors and obesity: a review.

Authors:  Mai A Elobeid; David B Allison
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-10       Impact factor: 3.243

Review 10.  Insulin, insulin receptors, and cancer.

Authors:  R Vigneri; I D Goldfine; L Frittitta
Journal:  J Endocrinol Invest       Date:  2016-07-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.